Amalgamated Financial’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Amalgamated Financial’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$2.33M	Buy	+22,095	New	+$2.15M	0.02%	846

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amalgamated Financial's HZNP Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2022: 22,095 shares worth $2.33M. The stake represents 0.02% of the portfolio and ranks #846 among its holdings.

620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.

Amalgamated Financial held 22,095 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $2.33M as of Q1 2022.
Horizon Therapeutics Public Limited Company Ordinary Shares was a new Amalgamated Financial position in Q1 2022.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.02% of Amalgamated Financial's portfolio in Q1 2022, its #846 holding.
620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.